Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
- Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study
- The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology
- The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022
- Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market
Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study.
Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for a variety of conditions, including, but not limited to hypertension and heart disease. The success of this sildenafil study lives up to that resolve and sets the stage for more successful studies to come.
“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” he noted (https://nnw.fm/T0NED).
He also added that in 2022 the company would explore the technology for the potential treatment of hormone replacement, rheumatoid disease, dementia, diabetes, and erectile dysfunction.
The recent sildenafil study explored DehydraTECH’s processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”), sildenafil, for the potential application in erectile dysfunction management. It revealed that DehydraTECH delivered 74% more sildenafil into the bloodstream on average compared to the concentration-matched, generic control formulation (https://nnw.fm/WcVXM).
The success of this study could be beneficial to key brands such as Viagra or its generic pharmaceutical competitors. It also presents an opportunity for Lexaria to create even more value for its shareholders.
The company plans to kick off what it refers to as the most extensive hypertension study in April of this year. Its execution and subsequent completion will allow Lexaria to stamp its position as a global drug delivery market leader. The estimated current global market for drugs used to treat various heart diseases is $96.1 billion and expected to be $107.8 billion in 2025. (https://nnw.fm/MW0EF).
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder,” noted Mr. Bunka.
“Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” he added (https://nnw.fm/I13Sg).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study
- The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology
- The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022
- Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market
Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study.
Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for a variety of conditions, including, but not limited to hypertension and heart disease. The success of this sildenafil study lives up to that resolve and sets the stage for more successful studies to come.
“Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” he noted (https://nnw.fm/T0NED).
He also added that in 2022 the company would explore the technology for the potential treatment of hormone replacement, rheumatoid disease, dementia, diabetes, and erectile dysfunction.
The recent sildenafil study explored DehydraTECH’s processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”), sildenafil, for the potential application in erectile dysfunction management. It revealed that DehydraTECH delivered 74% more sildenafil into the bloodstream on average compared to the concentration-matched, generic control formulation (https://nnw.fm/WcVXM).
The success of this study could be beneficial to key brands such as Viagra or its generic pharmaceutical competitors. It also presents an opportunity for Lexaria to create even more value for its shareholders.
The company plans to kick off what it refers to as the most extensive hypertension study in April of this year. Its execution and subsequent completion will allow Lexaria to stamp its position as a global drug delivery market leader. The estimated current global market for drugs used to treat various heart diseases is $96.1 billion and expected to be $107.8 billion in 2025. (https://nnw.fm/MW0EF).
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder,” noted Mr. Bunka.
“Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” he added (https://nnw.fm/I13Sg).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
